This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Caprelsa (vandetanib)
General Description:
Caprelsa (vandetanib) is an oral targeted therapy indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. It works by inhibiting multiple kinases involved in tumor growth and progression, helping to slow disease advancement and improve patient outcomes.
Caprelsa is administered orally as tablets, with the dosage determined by a healthcare professional based on the patient’s condition and tolerance. Regular monitoring is required to manage potential side effects and ensure treatment effectiveness.
Getting Caprelsa (vandetanib) in India
Caprelsa is approved in several countries and recognized for its efficacy in treating medullary thyroid cancer. In India, where it may not yet be commercially available, patients can access Caprelsa legally through a Named Patient Program (NPP) under the supervision of a licensed physician.
MitoGENE helps Indian patients obtain Caprelsa (vandetanib) safely and efficiently, handling all necessary regulatory approvals, import permits, and logistics to ensure a secure and transparent process.
Available Dosage Form & Package:
• 100 mg tablets, 30 tablets per pack
• 300 mg tablets, 30 tablets per pack
Usage:
Oral Tablets
Disease Indication:
• Medullary Thyroid Cancer (MTC) / Unresectable Locally Advanced or Metastatic MTC
Manufacturer:
Sanofi-Aventis
Shipping:
Cold Chain Shipping
Onivyde requires cold chain shipping to protect its stability from heat, light, and handling. Specialized medical couriers use temperature-controlled packaging and vehicles to maintain optimal conditions, ensuring the medicine remains safe and effective during transit.
How to Access Caprelsa (vandetanib) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Caprelsa (vandetanib) is not yet approved or commercially available in India, MitoGENE can assist you in accessing it legally through the Named Patient Program (NPP). Here’s how the process works:
